Is Hims & Hers Health (HIMS) A Bargain After The Fraud Lawsuit Claims?

Hims & Hers Health (HIMS) is back in focus after a proposed securities fraud class action accused the telehealth provider of misleading investors about data sharing practices and prescription billing workflows.

Recent price action for Hims & Hers Health has been choppy, with the share price slipping about 1% over the past day and week, climbing 4.7% over the past month, yet falling 24.2% across 90 days. The 1-year total shareholder return is down 44.8%, despite a very large 3-year gain that still leaves long-term holders well ahead.

Balance your view on Hims & Hers Health by scanning a hand picked group of resilient healthcare names in the 31 resilient stocks with low risk scores before legal and regulatory headlines drive the next move.

Hims & Hers Health trades near US$29 with a wide gap between the recent slide in sentiment and a price target near US$31. Does fair value sit closer to that modest upside or far below it once legal risk is factored in?

Most Popular Narrative: 83% Undervalued

Hims & Hers Health closed at $29, while the most followed valuation narrative pegs fair value near $171. This wide gap turns the recent legal headlines into only one piece of a much bigger puzzle.

Over ten years, Hims & Hers has an unusually large addressable market ahead. That is why growth is not slowing down for a long time.

Growth comes from several reinforcing dimensions.

See why 79 investors see Hims & Hers Health as 83% undervalued.

Result: Fair Value of $171.19 (UNDERVALUED)

Still, two pressure points could quickly test this Hims & Hers Health narrative: any legal finding on data practices, and a slower shift toward profitability from current net losses.

Find out about the key risks to this Hims & Hers Health narrative.

Another Take On Hims & Hers Health’s Valuation

The popular narrative values Hims & Hers Health at $171 per share, which points to a very large upside from the current $29. The market based view using a P/S of 2.6x tells a different story when set against the US Healthcare industry at 1.3x and peers at 2.2x. A fair ratio of 4.6x suggests sentiment could still shift a long way in either direction as legal risks and execution play out.

For a closer look at how this pricing gap stacks up against peers and the fair ratio estimate, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages and split sentiment on Hims & Hers Health can be useful if you treat them as raw material rather than a verdict. Move quickly. Test the numbers and legal headlines against your own risk tolerance, then weigh both sides with the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Hims & Hers Health?

If Hims & Hers Health has sharpened your thinking on risk and reward, you might choose to use that momentum and look for other opportunities before the market moves first.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]